A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.
|
| Abstract |
Lomeguatrib, an O(6)-methylguanine-DNA methyltransferase inactivator, was evaluated in an extended dosing regimen with temozolomide, designed according to pharmacodynamic data from previous studies. Patients with unresectable stage 3 or 4 cutaneous or unknown primary melanoma metastases were treated with lomeguatrib 40 mg, b.i.d. for 10 or 14 days and temozolomide 75-100 mg m(-2) on days 1-5. Drugs were administered orally with cycles repeated every 28 days, for up to six cycles. A total of 32 patients were recruited to the study. Lomeguatrib for 10 days with temozolomide 75 mg m(-2) was established as the optimal extended lomeguatrib dosing schedule, with haematological toxicity being dose limiting. There were two partial responses to treatment giving an overall response rate of 6.25%. Extending lomeguatrib administration beyond that of temozolomide requires a reduced dose of the latter agent. Only limited clinical activity was seen, suggesting no advantage for this regimen over conventional temozolomide administration in the treatment of melanoma.
|
|---|---|
| Authors | R F Kefford, N P B Thomas, P G Corrie, C Palmer, E Abdi, D Kotasek, J Beith, M Ranson, P Mortimer, A J Watson, G P Margison, M R Middleton |
| Journal | British journal of cancer (Br J Cancer) Vol. 100 Issue 8 Pg. 1245-9 (Apr 21 2009) ISSN: 1532-1827 [Electronic] England |
| PMID | 19367282 (Publication Type: Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!